SCHEMBL2471502

SCHEMBL2471502

Cc1ccc(Cl)cc1-c1ccccc1C=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
TSHR P16473 1/20 0.47
TDP1 Q9NUW8 2/20 0.44
ERN1 O75460 3/20 0.42
S100A4 P26447 1/20 0.42
PLA2G7 Q13093 1/20 0.41
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
THRB P10828 1/20 0.40
BLM P54132 1/20 0.40
KMT2A Q03164 1/20 0.40
CHRM1 P11229 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
IDO1 P14902 1/20 0.38
KDM4E B2RXH2 1/20 0.38
CASP3 P42574 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6930919 0.85 TDP1 (0.55) ALDH1A1TSHRTDP1ERN1S100A4
SCHEMBL28533543 0.83 ALDH1A1 (0.47) ALDH1A1TSHRTDP1ERN1S100A4
SCHEMBL10041658 0.82 TDP1 (0.52) ALDH1A1TDP1ERN1S100A4MEN1
SCHEMBL6003472 0.82 ERN1 (0.52) ALDH1A1TSHRTDP1ERN1S100A4
SCHEMBL27547924 0.81 ERN1 (0.47) TDP1ERN1S100A4MEN1LMNA
SCHEMBL2477879 0.79 ALDH1A1 (0.47) ALDH1A1TSHRTDP1ERN1MEN1
SCHEMBL31488266 0.79 ERN1 (0.59) ALDH1A1TDP1ERN1S100A4MEN1
SCHEMBL13350048 0.79 ERN1 (0.59) ALDH1A1TDP1ERN1S100A4MEN1
SCHEMBL546960 0.79 TDP1 (0.44) ALDH1A1TSHRTDP1ERN1S100A4
SCHEMBL1765158 0.79 TSHR (0.67) ALDH1A1TSHRTDP1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2159216-B1 3-BUTENYL-1-AMINE DERIVATIVES AND THEIR USE AS Ih MODULORS FOR THE TREATMENT OF PSYCHIATIRC DISORDERS ORGANON NV (NL) 2011-10-12 EP disclosed
EP-2159216-A1 Ih - Modulators N.V. Organon (NL) 2010-03-03 EP disclosed
CN-101622227-A Biaryl and biheteroaryl compounds useful in treating iron disorders XENON PHARMACEUTICALS INC 2010-01-06 CN disclosed
US-20040229910-A1 Therapeutic compounds N.V. ORGANON (NL) 2004-11-18 US disclosed
US-20020037885-A1 Therapeutic compounds DIJCKS FREDERICUS ANTONIUS (NL) 2002-03-28 US disclosed
US-6313139-B1 ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS AKZO NOBEL N. V. (NL) 2001-11-06 US disclosed
EP-1035843-A2 I h?-MODULATORS Akzo Nobel N.V. (NL) 2000-09-20 EP disclosed
US-6080773-A USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS AKZO NOBEL, N.V. (NL) 2000-06-27 US disclosed
WO-1999018941-A2 Ih-MODULATORS AKZO NOBEL N.V. (NL) 1999-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229910-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 ALDH1A1 964/4885TSHR 2499/4885TDP1 2228/4885
US-20020037885-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 ALDH1A1 964/4885TSHR 2499/4885TDP1 2228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.